Two Cases of Inflammatory Bowel Disease Patients Treated With Ustekinumab 90 mg Every 3 Weeks.

Inflamm Bowel Dis

Department of Hepato-Gastroenterology, University Hospital of Grenoble, University of Grenoble Alpes, Grenoble, France.

Published: January 2020

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz291DOI Listing

Publication Analysis

Top Keywords

cases inflammatory
4
inflammatory bowel
4
bowel disease
4
disease patients
4
patients treated
4
treated ustekinumab
4
ustekinumab weeks
4
cases
1
bowel
1
disease
1

Similar Publications

The intestinal barrier function is a critical defense mechanism in the human body, serving as both the primary target and initiating organ in cases of sepsis. Preserving the integrity of this barrier is essential for preventing complications and diseases, including sepsis and mortality. Despite this importance, the impact of resveratrol on intestinal barrier function remains unclear.

View Article and Find Full Text PDF

Introduction: Traumatic brain injury (TBI) is a major cause of disability and mortality worldwide. Acute traumatic subdural hematoma (TSDH) accounts for a large proportion of all TBI cases. However, factors to predict postoperative prognosis in patients with acute TSDH are limited.

View Article and Find Full Text PDF

Background: Case reports suggest that calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) may trigger inflammatory flares in patients with autoimmune diseases.

Case Description: A 56-year-old woman with a history of severe migraines, experienced improvement in migraine frequency and intensity after starting fremanezumab 225 mg monthly. However, three months into treatment, she developed symmetric inflammatory polyarthralgias.

View Article and Find Full Text PDF

Psoriasis is a noncontagious, autoimmune chronic inflammatory disease with an unknown root cause. It is classified as a multifactorial and chronic skin disorder that also affects the immune system and is genetic. Environmental factors such as stress, infections, and injuries all play an important role in the disease's development.

View Article and Find Full Text PDF

Comparative clinical and incremental cost-effectiveness analysis of treatments for pelvic inflammatory disease in southern Brazil.

Int J Gynaecol Obstet

January 2025

Postgraduate Program in Medicine, Surgical Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.

Objective: This paper evaluates the accuracy of C-reactive protein (CRP), leukocyte count, and neutrophil-to-lymphocyte ratio (NLR) for diagnosing tubo-ovarian abscess (TOA) and assessing the cost-effectiveness of different treatment regimens for pelvic inflammatory disease (PID), with and without TOA.

Method: A retrospective cohort study was conducted between January 1, 2003, and December 30, 2021, including women aged 13-80 years diagnosed with PID. The analysis focused on the incremental cost-effectiveness ratio of different treatment regimens.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!